Latigo Biotherapeutics(NASDAQ) LTGO

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative non-opioid pain medicines. The company aims to provide effective solutions for pain management without the risk of addiction, addressing a significant need in the healthcare sector.

Products and Services

• Molecule: LTG-001, a non-opioid pain relief option
• Molecule: LTG-32, targeting rapid pain transmission cessation
• Molecule: LTG-418, designed for intravenous administration

Growth Outlook

• Market demand for non-opioid pain solutions is increasing
• Clinical trials are progressing, enhancing product validation
• Strategic partnerships may expand market reach and capabilities

Financial Highlights

• Market capitalization stands at approximately $1.39 billion
• Stock price has fluctuated between $17.22 and $25.93 in the past year
• Average trading volume is around 373,071 shares

Latigo Biotherapeutics Inc. is positioned in the healthcare sector, specifically within the medical pharmaceuticals industry. The company is headquartered in Thousand Oaks, California, and employs 59 individuals. With a focus on innovative pain management solutions, Latigo is addressing a critical issue in healthcare, particularly as the opioid crisis continues to impact society. The company's product pipeline includes several promising molecules that aim to provide effective pain relief without the associated risks of addiction. As the market for non-opioid alternatives grows, Latigo's strategic initiatives and clinical advancements may enhance its competitive position and drive future growth.